ArticleNeuropsychiatric disease and treatment2008
Prophylaxis of migraine: general principles and patient acceptance.
Article in Neuropsychiatric disease and treatment, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials.Scientific reports · 2020Pooled it
- A systematic review of the psychosocial difficulties relevant to patients with migraine.The journal of headache and pain · 2012Pooled it
- Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.The journal of headache and pain · 2022Trial
- Trial
- Trial
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine.The journal of headache and pain · 2018Trial
- Trial
- Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up.The journal of headache and pain · 2017Trial
- TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.Neurology · 2016Trial
- Practice-Based Consensus Amongst Indian Neurologists: Adopting Remote Electrical Neuromodulation for Effective Management of Migraine.Advances in therapy · 2026Article
- Advances in Migraine Treatment: A Comprehensive Clinical Review.Current protein & peptide science · 2025Review
- The effect of lavender aromatherapy and acetaminophen as preemptive on comfort and Nitroglycerin-induced headache in acute coronary syndrome.ARYA atherosclerosis · 2025Article
- Efficacy of Desvenlafaxine in Reducing Migraine Frequency and Severity: A Retrospective Study.Journal of clinical medicine · 2024Article
- MigraineTracker: Examining Patient Experiences with Goal-Directed Self-Tracking for a Chronic Health Condition.Proceedings of the SIGCHI conference on human factors in computing systems. CHI Conference · 2024Article
- The Feasibility and Acceptability of a Data Capture Methodology in Pediatric Cancer Patients Treated with Targeted Agents and Immunotherapies.Current oncology (Toronto, Ont.) · 2024Article
- CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine.Medicina (Kaunas, Lithuania) · 2024Review
- Migraine Treatment: Towards New Pharmacological Targets.International journal of molecular sciences · 2023Review
- Discrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine.Neurology and therapy · 2023Article
- Development of the functional assessment of migraine scale using a patient guided approach.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- The Functional Assessment of Migraine Scale development datasets.Data in brief · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a chronic neurological condition with episodic exacerbations. Migraine is highly prevalent, and associated with significant pain, disability, and diminished quality of life. Migraine management is an important health care issue. Migraine management includes avoidance of trigger factors, lifestyle modifications, non-pharmacological therapies, and medications. Pharmacological treatment is traditionally divided into acute or symptomatic treatment, and preventive treatment or prophylaxis. Many migraine patients can be treated using only acute treatment. Patients with severe and/or frequent migraines require long-term preventive therapy. Prophylaxis requires daily administration of anti-migraine compounds with potential adverse events or contraindications, and may also interfere with other concurrent conditions and treatments. These problems may induce patients to reject the idea of a preventive treatment, leading to poor patient adherence. This paper reviews the main factors influencing patient acceptance of anti-migraine prophylaxis, providing practical suggestions to enhance patient willingness to accept pharmacological anti-migraine preventive therapy. We also provide information about the main clinical characteristics of migraine, and their negative consequences. The circumstances warranting prophylaxis in migraine patients as well as the main characteristics of the compounds currently used in migraine prophylaxis will also be briefly discussed, focusing on those aspects which can enhance patient acceptance and adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.